Annuncio pubblicitario
Italia markets close in 6 hours 56 minutes

  • FTSE MIB

    33.738,63
    +109,42 (+0,33%)
     

  • Dow Jones

    38.675,68
    +449,98 (+1,18%)
     

  • Nasdaq

    16.156,33
    +315,33 (+1,99%)
     

  • Nikkei 225

    38.236,07
    -38,03 (-0,10%)
     

  • Petrolio

    78,86
    +0,75 (+0,96%)
     

  • Bitcoin EUR

    60.654,53
    +1.445,26 (+2,44%)
     

  • CMC Crypto 200

    1.392,99
    +80,36 (+6,12%)
     

  • Oro

    2.329,50
    +20,90 (+0,91%)
     

  • EUR/USD

    1,0778
    +0,0012 (+0,11%)
     

  • S&P 500

    5.127,79
    +63,59 (+1,26%)
     

  • HANG SENG

    18.578,30
    +102,38 (+0,55%)
     

  • Euro Stoxx 50

    4.923,65
    +2,17 (+0,04%)
     

  • EUR/GBP

    0,8565
    -0,0013 (-0,15%)
     

  • EUR/CHF

    0,9744
    +0,0009 (+0,09%)
     

  • EUR/CAD

    1,4736
    +0,0011 (+0,08%)
     

Avenue Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference

Avenue Therapeutics
·1 minuto per la lettura
Avenue Therapeutics
Avenue Therapeutics

MIAMI, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer, will present a corporate update at the H.C. Wainwright 25th Annual Global Investment Conference scheduled to take place September 11-13, 2023. The presentation will be available for on-demand viewing starting Monday, September 11, 2023 at 7:00 a.m. ET.

A webcast and subsequent archived replay of the company presentation will be available on the Events page of Avenue’s website: https://avenuetx.com/ for approximately 30 days following the meeting.

About Avenue Therapeutics

Avenue Therapeutics, Inc. (Nasdaq: ATXI) is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. It is currently developing three assets including AJ201, a first-in-class oral small molecule for spinal and bulbar muscular atrophy, BAER-101, an oral small molecule selective GABA-A α2/3 receptor positive allosteric modulator for CNS diseases, and IV tramadol, which is in Phase 3 clinical development for the management of moderate-to-moderately-severe pain in adults in a medically supervised healthcare setting. Avenue is headquartered in Miami, FL and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). For more information, visit www.avenuetx.com.

Contact:
Jaclyn Jaffe
Avenue Therapeutics, Inc.
(781) 652-4500
ir@avenuetx.com